NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...

NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...

For a thorough assessment of NVAX stock, go to TipRanks’ Stock Analysis page. Trending Articles Novavax NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.

Data from Benzinga Pro shows a consensus estimate of $(0.83) as adjusted EPS loss and revenues of $65.8 million. Price Action: At last check on Monday, NVAX stock was up 14.30% to $10.18 during the ...